Scintigraphic prediction of resistance to radiation and chemotherapy in patients with lung carcinoma

Fukumoto, Mitsutaka; Yoshida, Daisuke; Hayase, Naoko; Kurohara, Atsushi; Akagi, Naoki; Shoji, Yasuhiro

doi:10.1002/(sici)1097-0142(19991015)86:8<1470::aid-cncr13>3.0.co;2-s

Cited by 27 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other groups have also demonstrated a correlation between [ 99m Tc(tetrofosmin) 2 O 2 ] + retention and therapeutic resistance in patients with lung cancer. 146 In musculoskeletal tumours, Soderlund found a wide variability in tumour/background ratios that were attributed in part to differing expression of Pgp, 147 while Yapar et al reported that Pgp overexpression was not related with [ 99m Tc(tetrofosmin) 2 O 2 ] + uptake but with washout rate. 148 [ 99m Tc(tetrofosmin) 2 O 2 ] + has similar but not identical properties to those of [ 99m Tc(MIBI) 6 ] + , therefore clinical studies involving functional imaging of MDR and in vivo modulation of MDR could be performed with [ 99m Tc(tetrofosmin) 2 O 2 ] + or [ 99m Tc(MIBI) 6 ] + , but the two should probably not be used interchangeably.…”

Section: Tc(v) Oxocomplexesmentioning

confidence: 99%

Metalloprobes for functional monitoring of tumour multidrug resistance by nuclear imaging

Mendes¹,

Paulo²,

Santos³

2011

Dalton Trans.

View full text Add to dashboard Cite

Cancer chemotherapy has been used since the early 1950s and still remains one the major therapeutic options for many malignant tumours. A major obstacle to successful cancer chemotherapy is drug resistance. Frequently resistance is intrinsic to the cancer, but as therapy becomes more effective, acquired resistance has also become more frequent. One form of resistance, named multidrug resistance (MDR), is responsible for the failure of tumours to respond to a wide spectrum of chemotherapeutic agents. The in vivo monitoring of MDR could assist in the selection of patients for therapy and can avoid ineffective and potentially toxic treatments. Therefore, methods for functionally interrogating MDR transport activity have been sought, namely single photon emission computed tomography (SPECT) and positron emission tomography (PET). Cationic radiotracers originally developed as SPECT myocardial imaging agents, such as [(99m)Tc(MIBI)(6)](+) and [(99m)Tc(tetrofosmin)(2)O(2)](+), are used for both early cancer detection and non-invasive monitoring of the tumour MDR transport function. With the ultimate goal of obtaining better performing radioprobes for MDR imaging, other metal-based complexes and/or small molecules have also been synthesized and biologically evaluated. In this perspective we will report on the chemical efforts made to find metalloprobes for in vivo monitoring of MDR by nuclear imaging techniques. The current knowledge on the biological mechanisms and proteins involved in tumour MDR will be also briefly presented, as its understanding is invaluable for the rational design and biological evaluation of new radioprobes.

show abstract

Section: Tc(v) Oxocomplexesmentioning

confidence: 99%

Metalloprobes for functional monitoring of tumour multidrug resistance by nuclear imaging

Mendes¹,

Paulo²,

Santos³

2011

Dalton Trans.

View full text Add to dashboard Cite

show abstract

“…The realization of this strategy has been demonstrated in several proof-of-principle clinical trials. The conclusion of these studies was that both substances are able to predict multidrug-resistance of tumors caused by P-glycoprotein [50-53]. 99m Tc-sestamibi revealed P-glycoprotein specificity in cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Transport processes of radiopharmaceuticals and -modulators

Efferth

Langguth

2011

Radiat Oncol

View full text Add to dashboard Cite

Radiotherapy and radiology have been indispensable components in cancer care for many years. The detection limit of small tumor foci as well as the development of radio-resistance and severe side effects towards normal tissues led to the development of strategies to improve radio-diagnostic and -therapeutic approaches by pharmaceuticals. The term "radiopharmaceutical" has been used for drugs labeled with radioactive tracers for therapy or diagnosis. In addition, drugs have been described to sensitize tumor cells to radiotherapy (radiosensitizers) or to protect normal tissues from detrimental effects of radiation (radioprotectors). The present review summarizes recent concepts on the transport of radiopharmaceuticals, radiosensitizers, and radioprotectors in cells and tissues, e.g. by ATP-binding cassette transporters such as P-glycoprotein. Strengths and weaknesses of current strategies to improve transport-based processes are discussed.

show abstract

Molecular imaging of gene expression and protein function in vivo with PET and SPECT

Sharma¹,

Luker²,

Piwnica‐Worms³

2002

Magnetic Resonance Imaging

127

View full text Add to dashboard Cite

Molecular imaging is broadly defined as the characterization and measurement of biological processes in living animals, model systems, and humans at the cellular and molecular level using remote imaging detectors. One underlying premise of molecular imaging is that this emerging field is not defined by the imaging technologies that underpin acquisition of the final image per se, but rather is driven by the underlying biological questions. In practice, the choice of imaging modality and probe is usually reduced to choosing between high spatial resolution and high sensitivity to address a given biological system. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) inherently use image-enhancing agents (radiopharmaceuticals) that are synthesized at sufficiently high specific activity to enable use of tracer concentrations of the compound (picomolar to nanomolar) for detecting molecular signals while providing the desired levels of image contrast. The tracer technologies strategically provide high sensitivity for imaging small-capacity molecular systems in vivo (receptors, enzymes, transporters) at a cost of lower spatial resolution than other technologies. We review several significant PET and SPECT advances in imaging receptors (somatostatin receptor subtypes, neurotensin receptor subtypes, ␣ v ␤ 3 integrin), enzymes (hexokinase, thymidine kinase), transporters (MDR1 P-glycoprotein, sodium-iodide symporter), and permeation peptides (human immunodeficiency virus type 1 (HIV-1) Tat conjugates), as well as innovative reporter gene constructs (herpes simplex virus 1 thymidine kinase, somatostatin receptor subtype 2, cytosine deaminase) for imaging gene promoter activation and repression, signal transduction pathways, and protein-protein interactions in vivo.

show abstract

Scintigraphic prediction of resistance to radiation and chemotherapy in patients with lung carcinoma

Cited by 27 publications

References 31 publications

Metalloprobes for functional monitoring of tumour multidrug resistance by nuclear imaging

Metalloprobes for functional monitoring of tumour multidrug resistance by nuclear imaging

Transport processes of radiopharmaceuticals and -modulators

Molecular imaging of gene expression and protein function in vivo with PET and SPECT

Contact Info

Product

Resources

About